B7-H3 is eligible for predicting clinical outcomes in lung adenocarcinoma patients treated with EGFR tyrosine kinase inhibitors.
B7-H3 is eligible for predicting clinical outcomes in lung adenocarcinoma patients treated with EGFR tyrosine kinase inhibitors.
复制标题
B7-H3 适合预测接受 EGFR 酪氨酸激酶抑制剂治疗的肺腺癌患者的临床结果
DOI：
10.1186/s12957-022-02634-x
复制
发表时间：
2022-05-20
影响因子：
3.2
通讯作者：
Chen, Li-wen
中科院分区：
文献类型：
--
作者：
Yang, Ying;Huang, Jun-feng;Hu, Bing-qi;Zhou, Jing;Wang, Xian;Feng, Zhen-zhong;Chen, Yu-ting;Pan, Fa-ming;Cheng, Huai-dong;Chen, Li-wen
并不是所有具有激活表皮生长因子受体(EGFR)突变的肺腺癌(LUAD)患者对酪氨酸激酶抑制剂(TKIs)有预期的反应。因此，需要生物标记物来确定从EGFR靶向治疗中获益最多的患者。我们先前的体外数据表明，基于B7-H3诱导的信号和EGFR信号之间的潜在交联性，共信号分子B7-H3决定了EGFR-TKI Gefitinib对EGFR突变的LUAD细胞系的敏感性。我们检测了56例初治LUAD患者的原始活检组织中肿瘤B7-H3的表达，并分析了B7-H3的高/低表达与一线抗EGFR治疗的临床结果的关系。分析疗效的主要标准是总有效率(ORR)、疾病控制率(DCR)和无进展生存率(PFS)，其次是总生存率(OS)。在B7-H3高、低表达亚组中，有效率分别为16.0%(4/25)和74.2%(23/31)(p<；0.001)，有效缓解率分别为36.0%(9/25)和87.1%(27/31)(p<；0.001)。B7-H3高的PFS[中位数8.7，95%可信区间(CI)4.0-13.4]显著低于B7-H3低(中位数未达到)[HR6.54(95%可信区间2.18-19.60)，p=0.001]。B7-H3高组患者的中位OS为15.9(95%CI 10.0-21.8)个月，低B7-H3组为25.7(95%CI 9.0-42.4)个月[HR 2.08(95%CI 1.07-4.02)，P=0.03]。单变量和多变量分析均发现B7-H3是与PFS差(p=0.001，p=0.000)和OS(p=0.03，p=0.015)相关的独立因素。B7-H3可作为预测接受一线EGFR-TKI治疗的EGFR突变的LUAD患者临床结果的潜在生物标志物。网上版载有补充材料，可在10.1186/s12957-022-02634-x查阅。
Not all lung adenocarcinoma (LUAD) patients with activating epidermal growth factor receptor (EGFR) mutations respond to tyrosine kinase inhibitors (TKIs) as intended. Thus, biomarkers are needed to identify patients who benefit most from EGFR-targeted therapy. Our previous in vitro data has shown that the co-signal molecule B7-H3 determines EGFR-TKI gefitinib susceptibility of EGFR-mutated LUAD cell lines, based on the potential crosslinking between B7-H3-induced signaling and EGFR signaling. We detected tumoral B7-H3 expression in the original biopsy from 56 treatment-naïve LUAD patients and analyzed the association between high/low B7-H3 expression with the clinical outcomes of first-line anti-EGFR therapy. The main criteria for the analysis of response were overall response rate (ORR), disease control rate (DCR), and progression-free survival (PFS), and the secondary criterion was overall survival (OS). In the subgroups of B7-H3 high and low expression, the ORR were 16.0% (4/25) and 74.2% (23/31) (p<0.001), and the DCR were 36.0% (9/25) and 87.1% (27/31) (p<0.001), respectively. The PFS of B7-H3 high [median 8.7, 95% confidence interval (CI) 4.0–13.4] was significantly worse than that of B7-H3 low (median not reached) [HR 6.54 (95% CI 2.18–19.60), p=0.001]. The median OS was 15.9 (95% CI 10.0–21.8) months in the B7-H3 high cohort and 25.7 (95% CI 9.0–42.4) months in the B7-H3 low subjects [HR 2.08 (95% CI 1.07–4.02), p=0.03], respectively. Both the univariate and multivariate analyses identified B7-H3 as an independent factor associated with poor PFS (p=0.001, p=0.000) and OS (p=0.03, p=0.015). B7-H3 may serve as a potential biomarker to predict clinical outcomes in EGFR-mutated LUAD patients treated with first-line EGFR-TKIs. The online version contains supplementary material available at 10.1186/s12957-022-02634-x.
登录
查看更多内容
影响因子：
--
作者：
Ding M;Liao H;Zhou N;Yang Y;Guan S;Chen L
通讯作者：
Chen L
影响因子：
3.2
作者：
Yang W;Gao Y;Li X;Zhang J;Liu T;Feng X;Pan H;Yang X;Xie S;Feng X;Lv Z;Wang Y;Chen Z;He J
通讯作者：
He J
影响因子：
3.2
作者：
Wu LL;Lai JJ;Liu X;Huang YY;Lin P;Long H;Zhang LJ;Ma GW
通讯作者：
Ma GW
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
3.2
作者：
Jia E;Ren N;Guo B;Cui Z;Zhang B;Xue J
通讯作者：
Xue J